13-year mortality trends among hospitalized patients with inflammatory bowel disease by Justin L Sewell & Hal F Yee
Sewell and Yee BMC Gastroenterology 2012, 12:79
http://www.biomedcentral.com/1471-230X/12/79RESEARCH ARTICLE Open Access13-year mortality trends among hospitalized
patients with inflammatory bowel disease
Justin L Sewell* and Hal F Yee JrAbstract
Background: Studies document increasing rates of hospitalization among patients with inflammatory bowel disease, but
temporal trends for in-hospital mortality among patients with inflammatory bowel disease are not characterized. We
sought to determine whether in-hospital mortality changed over a 13-year period among nationwide hospitalizations
associated with inflammatory bowel disease. We additionally sought to identify factors correlated with mortality.
Methods: We used the National Hospital Discharge Survey, a large nationally representative database, for the years 1994
through 2006. Age- and mortality-adjusted rates of in-hospital mortality and standardized mortality ratios were calculated
for four time periods. Logistic regression analysis was used to assess associations between advancing time and mortality
in adjusted analyses.
Results: 150 (0.9%) of 17,393 hospitalizations for patients with inflammatory bowel disease ended in death. Age-adjusted
in-hospital mortality decreased from 3.6 deaths per 1,000 hospital days in 1994–96 to 2.4 per 1,000 in 2003–06; standardized
mortality ratio decreased from 0.33 to 0.27. Similar trends were seen for patients with ulcerative colitis, but mortality did not
change over time among patients with Crohn’s disease. Multivariable logistic regression analysis confirmed the significance
of these changes in mortality, with 17% decreased odds of in-hospital death per three-year period (P=0.012). Subject age
(OR 1.06 per year, P< 0.001), Charlson comorbidity index (OR 1.29 per 1-point increase, P< 0.001), and diagnosis of
ulcerative colitis (versus Crohn’s disease, OR 1.41, P= .042) were also associated with in-hospital mortality.
Conclusions: The odds of in-hospital mortality among hospitalized patients with inflammatory bowel disease decreased by
17% per 3-year period from 1994 to 2006 in analysis adjusted for age and comorbidity status, in this large, nationally
representative database. Multiple factors likely contribute to these trends.
Keywords: Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Hospitalization, Epidemiology, Mortality,
In-hospital mortality, OutcomesBackground
The inflammatory bowel diseases (Crohn’s disease and ul-
cerative colitis) are chronic, lifelong diseases that affect
nearly 1.5 million people in the United States and are asso-
ciated with significant morbidity [1]. Although management
of patients with inflammatory bowel disease (IBD) con-
tinues to evolve, measuring ambulatory IBD-related out-
comes in the US is difficult due to the fragmented nature of
the healthcare system. Patients with IBD are at increased
risk for hospitalization, with inpatient care accounting for
one-third of IBD-related healthcare costs [2]. In contrast
with the ambulatory setting, nationally representative* Correspondence: justin.sewell@ucsf.edu
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distribution, and reproduction in any mediumdatabases that record patient outcomes, including in-
hospital mortality, are publicly available. In-hospital mortal-
ity is a clinically important outcome that may be affected by
changes in IBD management over time. Although studies
have reported point estimates of in-hospital mortality [3,4],
temporal trends for in-hospital mortality among IBD
patients are not documented.
To address this gap in knowledge, we sought to deter-
mine whether age- and comorbidity adjusted rates of in-
hospital mortality changed among hospitalized IBD patients
from 1994 to 2006, using a large, nationally representative
sample of hospitalizations in the United States. We add-
itionally sought to identify variables correlated with in-
hospital mortality among patients with IBD.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Study design
We obtained data from the National Hospital Discharge
Survey (NHDS) for years 1994 through 2006. Data from
each survey year were downloaded electronically, where
they are publicly available through the NHDS website.
Hospitalizations including a diagnosis of Crohn’s disease
or ulcerative colitis were identified using International
Classification of Diseases, 9th edition (ICD9) codes.
Data source
The NHDS is an annual survey administered by the Centers
for Disease Control [5,6]. It collects data from a national
probability sample of approximately 500 hospitals in the
United States, and includes approximately 300,000 hospitali-
zations annually. Federal and military hospitals, hospitals in
the Department of Veterans Affairs, hospitals of institutions
(such as prisons), and hospitals with five or fewer inpatient
beds are excluded. Data collected include demographics,
hospital characteristics, hospitalization data, up to seven
ICD9 codes, and up to four procedure codes. Data collec-
tion and processing methods produce an unbiased, nation-
ally representative sample of hospital discharges each year.
No personally identifying data are included, so, the unit of
measurement is by hospitalization, rather than by patient.
Inclusion and exclusion criteria
Hospitalizations including ICD9 codes 555.xx (for Crohn’s
disease) or 556.xx (for ulcerative colitis) were identified.
Records including diagnostic codes for both Crohn’s disease
and ulcerative colitis were categorized as having the disease
that was listed first in order. We excluded children based
on age of 17 years and younger. We further excluded
patients over the age of 99, as patients age 100 and older
are given an age of “202” in the NHDS, which would inter-
fere with statistical analysis.
Variables, data sources & measurement
The dependent variable and primary outcome was in-
hospital mortality, which was identified by discharge con-
dition of “dead”. We calculated mortality rates per 1,000
hospital days, which were directly age-adjusted and
mortality-adjusted (using the Charlson comorbidity index)
to the total NHDS population. We calculated the Charlson
Index using ICD9 codes present within the NHDS. Inde-
pendent variables obtained directly from the NHDS
included age, gender, race, geographical region, and hos-
pital size. We characterized the primary reason for
hospitalization as the first listed ICD9 code.
Statistical analysis
We performed univariable analyses to compare IBD-
associated hospitalizations ending in death versus those not
ending in death. We compared categorical variables usingχ2 tests or Fisher’s exact test, as appropriate, and continuous
variables using two-tailed t-tests.
We divided the 13 years studied into three 3-year time
periods (1994–96, 1997–99, 2000–02) and one 4-year time
period (2003–06) for statistical analysis. We calculated age-
and comorbidity-adjusted in-hospital mortality rates, and
standardized mortality ratios (SMRs), using the overall adult
NHDS population as the reference standard. We used mul-
tivariable logistic regression analysis to evaluate the statis-
tical significance of time period on odds of death in models
adjusted for variables of clinical and statistical significance.
We performed three different sensitivity analyses. The
first excluded hospitalizations less than 2 days in length.
The second included only patients with a primary diag-
nosis of ulcerative colitis or Crohn’s disease (defined as
the first ICD9 code listed in the NHDS). The third sensi-
tivity analysis excluded hospitalizations with a primary
diagnosis of a cardiopulmonary disease that was among
the top 10 primary diagnoses in the overall sample.
Analyses were performed using Stata, versions 10 and
11 (Statacorp, College Station, TX). P-values of .05 or
less were the standard for statistical significance.
Ethical considerations
The Institutional Review Board of the University of
California San Francisco granted exempt status to this
study, because it is an analysis of publicly available data
and includes no identifying information of any kind.
Results
Study population & univariable associations with
mortality
17,393 hospitalizations included a diagnosis of IBD; 150
(0.9%) ended in death (Table 1). Subjects who died were
older than subjects who did not die (70.3 years versus
49.2 years, P< 0.0001). Thirty-nine percent of hospitaliza-
tions ending in death included a primary diagnosis of IBD
compared with 46% of hospitalizations not ending in death
(P=NS). Hospitalizations with ulcerative colitis were twice
as likely to end in death as hospitalizations with Crohn’s dis-
ease (1.3% versus 0.6%, P< 0.001). Hospitalizations ending in
death were associated with significantly higher Charlson indi-
ces than those not ending in death (0.7 versus 2.0, P< .001).
Top diagnoses
Ulcerative colitis was the primary diagnosis in 2,989 (49.0%)
of ulcerative colitis-associated hospitalizations. Crohn’s dis-
eases was the primary diagnosis in 4,999 (44.8%) of Crohn’s
disease-associated hospitalizations. Fifty-nine (0.74%) hospi-
talizations with IBD as the primary diagnosis ended in
death, as compared with 91 (0.97%) of hospitalizations with
IBD as a non-primary diagnosis (P=NS).
Table 2 summarizes the top 10 primary diagnoses for
IBD-associated hospitalizations ending in death and not






Age, years, mean (SD) 49.2 (18.8) 70.3 (16.1) <0.0001
Gender, No. (%)
Female 9,977 (57.9) 86 (57.3)
Male 7,266 (42.1) 64 (42.7)
Race, No. (%)
White 10,504 (60.9) 104 (69.3)
Black 1,569 (9.1) 7 (4.7) 0.03b
Asian 66 (0.4) 0 (0.0)
Native American 54 (0.3) 0 (0.0)
Other 371 (2.2) 1 (0.7)
Unknown 4,679 (27.1) 38 (25.3)
Geographical region, No. (%)
Northeast 4,214 (24.4) 40 (26.7)
Midwest 5,418 (31.4) 42 (28.0) 0.05c
South 5,637 (32.7) 43 (28.7) 0.04c
West 1,974 (11.5) 25 (16.7)
Number of beds in hospital, No. (%)
6-199 beds 5,482 (31.8) 56 (37.3)
200-499 beds 9,250 (53.6) 73 (48.7)
500+ beds 2,511 (14.6) 21 (14.0)
Disease subtype, No. (%) <0.001
Crohn’s disease 11,149 (64.7) 71 (47.3)
Ulcerative colitis 6,094 (35.3) 79 (52.7)
IBD as primary diagnosis, No. (%)d 7,929 (46.0) 59 (39.3)
Charlson comorbidity index, mean (SD) 0.7 (1.3) 2.0 (1.4) <0.001
a For categorical variables with more than two responses, comparisons were made between all possible pairs; only significant P-values are reported.
b Compared with whites.
c Compared with West region.
d A “primary” diagnosis of IBD indicates that the first-listed ICD9 code was either 555 or 556.
Sewell and Yee BMC Gastroenterology 2012, 12:79 Page 3 of 7
http://www.biomedcentral.com/1471-230X/12/79ending in death. Five diagnoses were among the top 10
in both groups: Crohn’s disease, ulcerative colitis, other
disorders of the intestine, pneumonia, and other forms
of chronic ischemic heart disease. Crohn’s disease and
ulcerative colitis were statistically more common pri-
mary diagnoses among hospitalizations not ending in
death. Five primary diagnoses related to cardiac and pul-
monary disease were statistically more common in hos-
pitalizations ending in death.In-hospital mortality: IBD
For hospitalizations associated with either ulcerative colitis
or Crohn’s disease, age- and comorbidity-adjusted rates of
in-hospital mortality decreased from 3.6 deaths per 1,000
hospital days in 1994–96 to 2.1 deaths per 1,000 hospital
days in 2000–02; there was subsequent slight increase to
2.4 deaths per 1,000 hospital days in 2003–06 (Figure 1).The standardized mortality ratio decreased from 0.33 in
1994–96 to 0.27 in 2003–06 (Figure 1). In multivariable lo-
gistic regression analysis, the odds of mortality among all
hospitalizations with IBD decreased by 17% per time
period studied year (P=0.012, Table 3). Hospitalizations
with ulcerative colitis had 41% increased odds of mortality
compared with Crohn’s disease-related hospitalizations
(P=0.042). Age and Charlson index were both positively
associated with mortality (P< 0.001 for both comparisons).In-hospital mortality: Ulcerative colitis
For hospitalizations associated with ulcerative colitis, the
age- and comorbidity-adjusted rate of in-hospital mor-
tality decreased from 4.1 deaths per 1,000 hospital days
in 1994–96 to 2.0 deaths per 1,000 hospital days in
2000–02; there was subsequent increase to 2.8 deaths
per 1,000 hospital days in 2003–06 (Figure 2). The
Table 2 Top 10 primary diagnoses among inflammatory bowel disease-associated hospitalizations, by death status
ICD-9 codea Alive at discharge, No. (%)b Dead at discharge, No. (%)b
555 (Crohn’s disease)c,d 4977 (28.9) 22 (14.7)
556 (ulcerative colitis)c,d 2952 (17.1) 37 (24.7)
560 (intestinal obstruction without mention of hernia) 737 (4.3) 2 (1.3)
276 (disorders of fluid, electrolyte, and acid–base balance) 323 (1.9) 1 (0.7)
569 (other disorders of intestine)c 322 (1.9) 4 (2.7)
296 (episodic mood disorders) 228 (1.3) 1 (0.7)
577 (diseases of pancreas) 211 (1.2) 0 (0.0)
486 (pneumonia)c 206 (1.2) 4 (2.7)
414 (other forms of chronic ischemic heart disease)c,e 195 (1.1) 3 (2.0)
578 (gastrointestinal hemorrhage) 179 (1.0) 1 (0.7)
410 (acute myocardial infarction)d,e 105 (0.6) 6 (4.0)
162 (malignant neoplasm of trachea, bronchus and lung)d 13 (0.007) 5 (3.3)
491 (chronic bronchitis)d,e 134 (0.8) 5 (3.3)
427 (cardiac dysrhythmias)d,e 153 (0.9) 4 (2.7)
428 (heart failure)d,e 105 (0.6) 3 (2.0)
a Diagnoses in the left column include those that were among the 10 most common primary diagnoses for patients who were alive and dead at the time of
discharge. Order of variable listing reflects the relative frequency among patients who were alive at discharge, followed by patients who were dead at discharge.
b Values in bold indicate that the diagnosis was among the top 10 for that column.
c Diagnosis is among the top 10 primary diagnoses for those alive at discharge and those dead at discharge.
d P< 0.05 comparing proportions among hospitalizations ending in death versus those not ending in death.
e ICD9 code used to exclude hospitalizations from third sensitivity analysis.
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1994–96 to 0.35 in 2003–06 (Figure 2). In multivariable
logistic regression analysis, odds of mortality decreased
by 20% per time period studied (P= 0.02, Table 3). Age
and Charlson index both retained a strong positive asso-
ciation with mortality (P< .001 for both variables).
In-hospital mortality: Crohn’s disease
For hospitalizations associated with Crohn’s disease, the











































Adjusted deaths per 1,000 hospital 
Figure 1 Mortality trends over time for hospitalizations associated widecreased numerically from 2.7 deaths per 1,000 hospital
days in 1994–96 to 1.8 deaths per 1,000 hospital days in
2000–02, and then increased to 2.1 deaths per 1,000 hos-
pital days in 2003–06. The standardized mortality ratio
was unchanged over the study period (0.23 in 1994–96 and
1997–99, and 0.22 in 2000–02 and 2003–06). In multivari-
able logistic regression, calendar period was not signifi-
cantly associated with mortality. However, age and
Charlson index had significant positive associations with























days Standardized mortality ratio
th IBD.
Table 3 Multivariable logistic regression of factors associated with mortality
OR (95% CI) P-value
All patients with IBD
Calendar perioda 0.83 (0.72,0.96) 0.012
Age, per year 1.06 (1.05,1.07) <0.001
Charlson index 1.29 (1.21,1.38) <0.001
Diagnosis of ulcerative colitis (versus Crohn’s disease) 1.41 (1.01,1.95) 0.042
Patients with ulcerative colitis
Calendar perioda 0.80 (0.66,0.97) 0.02
Age, per year 1.06 (1.04,1.08) <0.001
Charlson index 1.27 (1.15,1.40) <0.001
Patients with Crohn’s disease
Age, per year 1.06 (1.04,1.07) <0.001
Charlson index 1.31 (1.19,1.45) <0.001
a Compares four calendar periods studied; odds ratio represents odds per advancing calendar period.
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In logistic regression analysis excluding hospitalizations
of less than 2 days’ duration, there were only 20 deaths
among IBD associated hospitalizations. Diagnosis of ul-
cerative colitis was no longer statistically associated with
death. However, age, Charlson index, and time period
remained significantly associated with in-hospital mor-
tality, with magnitudes of association similar to the ini-
tial logistic regression analysis. Specifically, the odds of
in-hospital mortality decreased by 15% per calendar
period (adjusted OR 0.85, 95% confidence interval
0.73,0.99). In a similar sensitivity analysis of ulcerative
colitis-associated hospitalizations, time period retained a
significant statistical association (adjusted OR 0.80, 95%
CI 0.65,0.99).
In logistic regression analysis limited to hospitalizations












































Adjusted deaths per 1,000 hospital 
Figure 2 Mortality trends over time for hospitalizations associated wiprimary diagnosis there were 59 deaths. Only Charlson
index and age retained significant associations with in-
hospital mortality with magnitude of association similar to
the original logistic regression analysis. In this sensitivity
analysis, time period no longer retained a significant asso-
ciation with in-hospital mortality (adjusted OR 1.11, 95%
confidence interval 0.88,1.41).
In logistic regression analysis excluding hospitalizations
with a primary diagnosis of a cardiopulmonary disease
among the top 10 diagnoses (see Table 2), there were 129
deaths. Time period retained a significant association with
death, with odds of mortality decreasing by 14% per ad-
vancing time period (OR 0.86, 95% CI 0.735,0.996). Age
and Charlson index retained significant positive associa-
tions with death, with magnitude similar to the original re-
gression analysis. However, ulcerative colitis was no
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The management of IBD continues to evolve rapidly,
but temporal trends in population-level mortality have
not been previously reported. In-hospital mortality is an
important clinical outcome readily available through na-
tionally representative data (as opposed to ambulatory
outcomes, for which nationally representative data are
not readily available). In this study, we found that, over
the 13-year period from 1994 to 2006, the odds of in-
hospital mortality among hospitalizations associated
with IBD decreased by 17% per time period studied in
analysis adjusted for age and comorbidity. These trends
seem to be driven largely by hospitalizations associated
with ulcerative colitis. Adjusted analyses suggest that
trends are not likely explained by temporal changes in
age or comorbidity.
Prior studies of in-hospital mortality for patients with
IBD used samples collected through the Nationwide In-
patient Sample ranging from 1998 to 2005. These stud-
ies reported point estimates of in-hospital mortality, but
did not examine temporal trends in in-hospital mortality
[3,4,7-11]. Mortality rates for unselected IBD patients in
these studies ranged from 0.3 to 1.3% of hospital admis-
sions, or 0.6 to 1.2 deaths per 1,000 hospital days. We
found similar mortality rates, supporting the accuracy of
our primary outcome measure. Most patients who died
in our study were age 60 years or older. This is consist-
ent with prior studies, which showed that IBD confers a
markedly increased mortality risk among patients age
60 years and older [12].
Although our data do not permit exact identification
of driving forces behind these trends, they do permit
some speculation. Our analyses were adjusted for age
and comorbid status, using the Charlson index, which is
known to be an accurate measure of comorbidities. The
fact that time period remained significantly associated
with mortality suggests that reductions in mortality are
not primarily due to confounding by temporal trends in
age or comorbidity among hospitalizations included in
the NHDS. The NHDS uses a similar sampling protocol
each year, so our results are not likely confounded by
measurement bias. Furthermore, it is unlikely that the
disease process of IBD itself changed dramatically over
the 13 year time-period of our study.
The above factors lead to natural speculation that
improvements in healthcare could contribute to reduc-
tions in in-hospital mortality. Our sensitivity analyses
allow some commentary in three specific areas. The sen-
sitivity analysis limited to hospitalizations with a primary
diagnosis of IBD suggests that an improvement in IBD
care alone is not likely to account for reductions in mor-
tality. However, this analysis included a small number of
deaths (59 deaths) spread out over a 13-year period, lim-
iting the power of the analysis. Improvements in IBDcare would probably be better assessed in an ambulatory
setting. The sensitivity analysis excluding hospitaliza-
tions with a primary diagnosis of cardiopulmonary dis-
ease suggests that improved care for cardiopulmonary
diseases is not the sole driver of reductions in mortality.
Finally, the sensitivity analysis excluding brief hospitali-
zations suggests that trends are not likely due more fre-
quent hospitalizations for less ill patients, who would
likely have brief hospitalization durations. It is likely
than numerous factors contribute to the mortality trends
that we document. Importantly, though, our analyses
argue against confounding by changing age, comorbidity,
or hospitalization practices.
It is interesting that mortality trends among IBD-
associated hospitalizations appeared to be driven primarily
by hospitalizations associated specifically with ulcerative
colitis. Although ulcerative colitis accounted for only a
third of IBD-associated hospitalizations, more than half of
deaths were in hospitalizations with ulcerative colitis, and
ulcerative colitis conferred a 41% increased odds of death
compared with Crohn’s disease. Furthermore, mortality
reduced significantly over time in all IBD hospitalizations,
and in ulcerative colitis hospitalizations specifically, but
not in Crohn’s disease hospitalizations. Compared with
Crohn’s disease, hospitalizations with ulcerative colitis
were associated with a significantly higher mean age and
Charlson index, but these did not vary over time in ulcera-
tive colitis related hospitalizations (data not shown). Fur-
thermore, the proportion of ulcerative colitis associated
hospitalizations with a primary (versus secondary) diagno-
sis of IBD did not change over time (data not shown).
A major impetus for this study was the lack of studies
documenting temporal trends in IBD-related outcomes.
We chose to use inpatient data due to the lack of nation-
ally representative ambulatory data for patients with IBD.
Much of what we know about the course of IBD is drawn
from cohorts that, while well-characterized, are not na-
tionally representative [13-15]. This limits understanding
of changes in IBD course over time at a population level,
and underscores the need for prospectively collected, na-
tionally representative, ambulatory data in IBD.Conclusions
In summary, we document decreasing in-hospital mor-
tality among hospitalizations with IBD in the United
States from 1994 to 2006 in this large, nationally repre-
sentative database, using analyses adjusted for the im-
portant confounders of age and comorbidity. Multiple
factors likely contribute to these trends.
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